BR9815602A - Composição e processo para induzir uma respostaem células sensìveis de um animal para tratar umcancer - Google Patents

Composição e processo para induzir uma respostaem células sensìveis de um animal para tratar umcancer

Info

Publication number
BR9815602A
BR9815602A BR9815602-0A BR9815602A BR9815602A BR 9815602 A BR9815602 A BR 9815602A BR 9815602 A BR9815602 A BR 9815602A BR 9815602 A BR9815602 A BR 9815602A
Authority
BR
Brazil
Prior art keywords
composition
dna
animal
sensitive cells
response
Prior art date
Application number
BR9815602-0A
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Original Assignee
Bioniche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Inc filed Critical Bioniche Inc
Publication of BR9815602A publication Critical patent/BR9815602A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"COMPOSIçãO E PROCESSO PARA INDUZIR UMA RESPOSTAEM CéLULAS SENSìVEIS DE UM ANIMAL PARA TRATAR UMCANCER". A presente invenção refere-se a uma composição eprocesso úteis para normalizar a proliferação celular e morte celularem um organismo multicelular. A presente invenção refere-se,especificamente, a uma composição compreendendo um DNAbacteriano (B-DNA) e um primeiro veículo farmaceuticamenteaceitável, onde o B-DNA induz uma resposta em células sensíveisde um animal. A presente invenção refere-se, maisespecificamente, a uma composição compreendendo um DNAmicobacteriano (M-DNA) e um primeiro veículo farmaceuticamenteaceitável, onde o M-DNA inibe a proliferação de células sensíveisde um animal, induz a apoptose nas células sensíveis de umanimal e estimula as células sensíveis do sistema imune de umanimal a produzirem moléculas bioativas. Também são reveladosprocessos de fabricação da composição de M-DNA e processosde utilização da composição de M-DNA.
BR9815602-0A 1997-08-05 1998-08-05 Composição e processo para induzir uma respostaem células sensìveis de um animal para tratar umcancer BR9815602A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5477797P 1997-08-05 1997-08-05
US7511198P 1998-02-18 1998-02-18
US7506798P 1998-02-18 1998-02-18
US8631798P 1998-05-21 1998-05-21
PCT/CA1998/000744 WO1999007383A1 (en) 1997-08-05 1998-08-05 Composition and method for regulating cell proliferation and cell death

Publications (1)

Publication Number Publication Date
BR9815602A true BR9815602A (pt) 2001-12-11

Family

ID=27489673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9815602-0A BR9815602A (pt) 1997-08-05 1998-08-05 Composição e processo para induzir uma respostaem células sensìveis de um animal para tratar umcancer

Country Status (17)

Country Link
US (2) US6329347B1 (pt)
EP (1) EP1003525B1 (pt)
JP (2) JP4335435B2 (pt)
KR (1) KR100533576B1 (pt)
AT (1) ATE227996T1 (pt)
AU (1) AU736450B2 (pt)
BR (1) BR9815602A (pt)
CA (1) CA2299548C (pt)
DE (1) DE69809561T2 (pt)
DK (1) DK1003525T3 (pt)
ES (1) ES2187047T3 (pt)
HU (1) HU227921B1 (pt)
IL (3) IL134371A0 (pt)
NO (1) NO322450B1 (pt)
NZ (1) NZ502674A (pt)
PT (1) PT1003525E (pt)
WO (1) WO1999007383A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736450B2 (en) 1997-08-05 2001-07-26 Bioniche Urology Ip Inc. Composition and method for regulating cell proliferation and cell death
ES2238780T3 (es) * 1998-02-18 2005-09-01 Bioniche Life Sciences Inc. Tratamiento de cancer de vejiga mediante pared celular de mycobacterium phlei.
US6809081B1 (en) 1998-12-04 2004-10-26 Bioniche Life Sciences, Inc. Chemotherapeutic composition and method
WO2000033879A1 (en) * 1998-12-04 2000-06-15 Bioniche Life Sciences Inc. Method for the treatment of inflammation
DE69920506T2 (de) * 1998-12-04 2005-10-13 Bioniche Life Sciences Inc., London Chemotherapeutische zusammensetzung und verfahren
US6794368B1 (en) * 1999-04-01 2004-09-21 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells
ATE296106T1 (de) * 1999-04-01 2005-06-15 Bioniche Life Sciences Inc Zusammensetzung und methode zur induzierung von apoptosis in prostatakrebszellen mittels m-dna und mcc
WO2001022979A1 (en) * 1999-09-29 2001-04-05 Bioniche Life Sciences Inc. Method to disrupt mitochondrial function
CN101491536B (zh) * 1999-12-13 2012-07-04 拜昂尼科生命科学有限公司 治疗用合成寡核苷酸
US7125858B2 (en) 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US6673566B1 (en) 2002-01-10 2004-01-06 The United States Of America As Represented By The Secretary Of Agriculture Diagnosis of pathogen infections through analysis of nitrite production by antigen stimulated leukocytes
EP3299033A1 (en) 2006-07-25 2018-03-28 Lipoxen Technologies Limited N-terminal polysialylation
HUE052413T2 (hu) 2010-10-13 2021-04-28 Telesta Therapeutics Inc Bakteriális ribonukleinsav-sejtfalkészítmények és elõállítási és felhasználási módszereik

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (pt) 1971-11-19 1975-02-07 Anvar
CA1020460A (en) 1973-02-23 1977-11-08 Wellcome Foundation Limited (The) Isolation of immunostimulating glycopeptide from bacteria
US3976544A (en) 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
DK0681479T3 (da) 1993-01-29 1999-11-08 Vetrepharm Inc Immunterapeutisk præparat
AU736450B2 (en) 1997-08-05 2001-07-26 Bioniche Urology Ip Inc. Composition and method for regulating cell proliferation and cell death

Also Published As

Publication number Publication date
DE69809561T2 (de) 2003-09-25
US6326357B1 (en) 2001-12-04
DE69809561D1 (de) 2003-01-02
NO20000576L (no) 2000-04-04
EP1003525A1 (en) 2000-05-31
KR100533576B1 (ko) 2005-12-05
NO322450B1 (no) 2006-10-09
ATE227996T1 (de) 2002-12-15
AU736450B2 (en) 2001-07-26
CA2299548A1 (en) 1999-02-18
JP2001513504A (ja) 2001-09-04
IL134371A (en) 2007-07-24
CA2299548C (en) 2009-12-29
IL180924A (en) 2010-11-30
EP1003525B1 (en) 2002-11-20
DK1003525T3 (da) 2003-03-24
NO20000576D0 (no) 2000-02-04
KR20010022643A (ko) 2001-03-26
NZ502674A (en) 2002-06-28
HUP0003012A2 (hu) 2000-12-28
IL180924A0 (en) 2007-07-04
WO1999007383B1 (en) 1999-03-25
US6329347B1 (en) 2001-12-11
IL134371A0 (en) 2001-04-30
WO1999007383A1 (en) 1999-02-18
PT1003525E (pt) 2003-03-31
HUP0003012A3 (en) 2004-03-29
JP2008208140A (ja) 2008-09-11
AU8723698A (en) 1999-03-01
JP4335435B2 (ja) 2009-09-30
HU227921B1 (hu) 2012-06-28
ES2187047T3 (es) 2003-05-16

Similar Documents

Publication Publication Date Title
BR9815602A (pt) Composição e processo para induzir uma respostaem células sensìveis de um animal para tratar umcancer
Arthur et al. Selenium in the immune system
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
EP0788307A4 (en) MODULATION BY OLIGONUCLEOTIDES OF THE PROTEIN ASSOCIATED WITH MULTIPLE ANTI-CANCER RESISTANCE
MX9705954A (es) Formulaciones y metodos para reducir irritacion de la piel.
BR9912653A (pt) Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
BR9714385A (pt) Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
PT873312E (pt) Acidos arilsulfonamido hidroxamicos alfa-substituidos como inibidores de tnf-alfa e metaloproteinas de matriz
BR0107643A (pt) Composições e processos para a terapia e diagnóstico de c ncer de próstata
WO2004000094A8 (en) Predictive markers in cancer therapy
AU2003265556A1 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2002020846A3 (en) Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
Zhang et al. Isolation and characterization of ACTX-6: a cytotoxic L-amino acid oxidase from Agkistrodon acutus snake venom
Kulms et al. Mechanisms of UV‐induced signal transduction
BR9909624A (pt) Linhagens de células do sistema nervoso periférico (pns) e processos de utilização para as memas
Zilberstein et al. Surface analysis of ancient parchments via the EVA film: The Aleppo Codex
NO20014537L (no) AKT-nukleinsyrer, -polypeptider og anvendelse av disse
Suzuki et al. Anthraquinone derivatives as a new family of protein photocleavers
AU2672099A (en) Compositions and methods for wound healing
ATE203997T1 (de) Antiwachstumwirksame proteine aus oozyten von rana pipiens
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
DE69732857D1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
WO2003098223A3 (en) A method for killing cells by inhibiting histone activity in the cell

Legal Events

Date Code Title Description
TCP Change of proprietor's name pending
B25D Requested change of name of applicant approved
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/711 (2008.01), A61K 35/74 (2008.01), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO ESTABELECIDO PELOS ARTIGOS 8O E 13 E 25 DA LPI ( LEI 9279/96 )

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25B Requested transfer of rights rejected

Owner name: BIONICHE LIFE SCIENCES, INC. (CA)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]